Brief: Solid Biosciences Provides Interim Positive Clinical Update On Phase 1/2 Inspire Duchenne Trial
11/03/2026 17:02
March 11 (Reuters) - Solid Biosciences Inc SLDB.O: SOLID BIOSCIENCES PROVIDES INTERIM POSITIVE CLINICAL UPDATE ON PHASE 1/2 INSPIRE DUCHENNE TRIAL SOLID BIOSCIENCES INC - SGT-003 GENERALLY WELL TOLERATED WITH ENCOURAGING SAFETY PROFILE IN 40 PARTICIPANTS SOLID BIOSCIENCES INC - ROBUST MICRODYSTROPHIN EXPRESSION AND IMPROVED MUSCLE INTEGRITY OBSERVED AFTER SGT-003 TREATMENT SOLID BIOSCIENCES INC - ANTICIPATES DOSING FIRST PARTICIPANT IN IMPACT DUCHENNE TRIAL IN Q1 2026 SOLID BIOSCIENCES: PLANS FOR ADDITIONAL MEETINGS WITH FDA IN H1 2026 FOR GUIDANCE ON POTENTIAL ACCELERATED APPROVAL PATHWAY FOR SGT-003 Source text: ID:nGNX7nbJkY Further company coverage: SLDB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Solid Biosciences
See all newsMarketing Agreement To Advance Gene Therapy Delivery And Analytics
Solid Biosciences Q1 net loss widens on higher R&D costs
Solid Biosciences Q4 net loss widens on higher R&D costs
NASDAQ RESUMED AT 01:58 PM
Brief: Solid Biosciences Provides Interim Positive Clinical Update On Phase 1/2 Inspire Duchenne Trial